Development and preclinical evaluation of ovNDV-28: a chimeric Newcastle disease virus expressing human IL-2 for cancer therapy

Posted on
development-and-preclinical-evaluation-of-ovndv-28:-a-chimeric-newcastle-disease-virus-expressing-human-il-2-for-cancer-therapy
Development and preclinical evaluation of ovNDV-28: a chimeric Newcastle disease virus expressing human IL-2 for cancer therapy

References

  1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

    PubMed  Google Scholar 

  2. Zhang S, Rabkin SD. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?. Expert Opin Drug Discov. 2020;16(4):391–410.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Pathak U, Pal RB, Malik N. The viral knock: ameliorating cancer treatment with oncolytic Newcastle disease virus. Life. 2023;13:1626.

  4. Harper J, Burke S, Travers J, Rath N, Leinster A, Navarro C, et al. Recombinant Newcastle disease virus immunotherapy drives oncolytic effects and durable systemic antitumor immunity. Mol Cancer Therapeutics. 2021;20(9):1723–34.

    Article  Google Scholar 

  5. Zamarin D, Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol. 2012;7(3):347–67.

    Article  PubMed  Google Scholar 

  6. Robert M, Lorence MSR, O’Neil JamesD, Groene WilliamS, Miller JeffreyA, Mueller StephenN, Bamat MichaelK. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets. 2007;7(2):157–67.

    Article  Google Scholar 

  7. Hotte SbJ, Lorence RM, Hirte HW, Polawski SR, Bamat MK, O’Neil JD, et al. An optimized clinical regimen for the oncolytic virus PV701. Clin Cancer Res. 2007;13(3):977–85.

    Article  PubMed  Google Scholar 

  8. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002;20(9):2251–66.

    Article  PubMed  Google Scholar 

  9. Laurie SA, Bell JC, Atkins HL, Roach J, Bamat MK, O’Neil JD, et al. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res. 2006;12(8):2555–62.

    Article  PubMed  Google Scholar 

  10. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. 2006;13(1):221–8.

    Article  PubMed  Google Scholar 

  11. Zhong L, Gan L, Wang B, Wu T, Yao F, Gong W, et al. Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell. 2025;188(4):1119–36.e23.

    Article  PubMed  Google Scholar 

  12. Davar D, Carneiro BA, Dy GK, Sheth S, Borad MJ, Harrington KJ, et al. Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors. J ImmunoTherapy Cancer. 2024;12:e009336.

  13. Bai Y, Chen Y, Hong X, Liu X, Su X, Li S, et al. Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo. Sci Rep. 2018;8:11470.

  14. Keshavarz M, Nejad ASM, Esghaei M, Bokharaei-Salim F, Dianat-Moghadam H, Keyvani H, et al. Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis. Saudi J Biol Sci. 2020;27(1):47–52.

    Article  PubMed  Google Scholar 

  15. Römer-Oberdörfer, A ME, Mebatsion T, Buchholz UJ, Mettenleiter TC. Generation of recombinant lentogenic Newcastle disease virus Clone30. J Gen Virol. 1999;80:2987–95.

    Article  PubMed  Google Scholar 

  16. Hu Z, Ni J, Cao Y, Liu X. Newcastle disease virus as a vaccine vector for 20 years: a focus on maternally derived antibody interference. Vaccines. 2020;8:222.

  17. Buijs P, Van Nieuwkoop S, Vaes V, Fouchier R, Van Eijck C, Hoogen B. Recombinant immunomodulating lentogenic or mesogenic oncolytic Newcastle disease virus for treatment of pancreatic adenocarcinoma. Viruses. 2015;7(6):2980–98.

    Article  PubMed  PubMed Central  Google Scholar 

  18. He J, An Y, Qi J, Cui L, Yang K, Liu M, et al. The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model. J Med Virol. 2020;93(6):3890–8.

    Article  PubMed  Google Scholar 

  19. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642–62.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Welch BD, Paduch M, Leser GP, Bergman Z, Kors CA, Paterson RG, et al. Probing the functions of the paramyxovirus glycoproteins F and HN with a panel of synthetic antibodies. J Virol. 2014;88(20):11713–25.

    Article  PubMed  PubMed Central  Google Scholar 

  21. PDQ Integrative A, and Complementary Therapies Editorial Board. Newcastle Disease Virus (PDQ®)–Health Professional Version. National Cancer Institute. 2018.

  22. Schirrmacher V. Molecular mechanisms of anti-neoplastic and immune stimulatory properties of oncolytic Newcastle disease virus. Biomedicines. 2022;10:562.

  23. Muhammad S, Fan T, Hai Y, Gao Y, He J. Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies. Mol Cancer. 2023;22:121.

  24. Pachella LA, Madsen LT, Dains JE. The toxicity and benefit of various dosing strategies for interleukin-2 in metastatic melanoma and renal cell carcinoma. J Adv Practitioner Oncol. 2015;6:212–21.

  25. Im SJ, Lee K, Ha S-J. Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends. Exp Mol Med. 2024;56(9):1900–8.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Wu J, Bloch N, Chang AY, Bhavsar R, Wang Q, Crawford A, et al. A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies. Cell Rep Med. 2024;5:101747.

  27. Park M-S, Pan Z, He J, Rasoul LM, Liu Y, Che R, et al. Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) vector expressing foreign gene to enhance its anti-tumor effect. Plos One. 2016;11:e0164723.

  28. An Y, Liu T, He J, Wu H, Chen R, Liu Y, et al. Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model. J Biomed Sci. 2016;23:55.

  29. Marianna, Pap JB, Szeberényi József. Sensitivity of human malignant melanoma cell lines to Newcastle disease virus. Anticancer Res. 2015;35(10):5401–6.

    Google Scholar 

  30. Ramamurthy N, Pathak DC, D’Silva AL, Batheja R, Mariappan AK, Vakharia VN, et al. Evaluation of the oncolytic property of recombinant Newcastle disease virus strain R2B in 4T1 and B16-F10 cells in-vitro. Res Vet Sci. 2021;139:159–65.

    Article  PubMed  Google Scholar 

  31. Paldurai A, Kim S-H, Nayak B, Xiao S, Shive H, Collins PL, et al. Evaluation of the contributions of individual viral genes to Newcastle disease virus virulence and pathogenesis. J Virol. 2014;88(15):8579–96.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Tsurudome M, Ito M, Nishio M, Nakahashi M, Kawano M, Komada H, et al. Identification of domains on the fusion (F) protein trimer that influence the hemagglutinin-neuraminidase specificity of the F protein in mediating cell-cell fusion. J Virol. 2011;85(7):3153–61.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Liao W, Lin J-X, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol. 2011;23(5):598–604.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Den Otter W, Jacobs JJL, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, et al. Local therapy of cancer with free IL-2. Cancer Immunol Immunother. 2008;57(7):931–50.

    Article  Google Scholar 

  35. Wang H, Borlongan M, Hemminki A, Basnet S, Sah N, Kaufman HL, et al. Viral vectors expressing interleukin 2 for cancer immunotherapy. Hum Gene Ther. 2023;34(17-18):878–95.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Fulber JPC, Farnós O, Kiesslich S, Yang Z, Dash S, Susta L, et al. Process development for Newcastle disease virus-vectored vaccines in serum-free vero cell suspension cultures. Vaccines. 2021;9:1335.

  37. Zamarin D, Wolchok JD. Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. Mol Therapy Oncolytics. 2014;1:14004.

  38. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–90.

    Article  PubMed  Google Scholar 

  39. Koehler T, Crawford MA, Burdick MD, Glomski IJ, Boyer AE, Barr JR, et al. Interferon-inducible CXC Chemokines directly contribute to host defense against inhalational anthrax in a murine model of infection. PLoS Pathogens. 2010;6:e1001199.

  40. Karin N. CXCR3 ligands in cancer and autoimmunity, chemoattraction of effector t cells, and beyond. Front Immunol. 2020;11:976.

  41. Shen Y, Song W, Lin D, Zhang X, Wang M, Li Y, et al. VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. J Med Virol. 2022;95:e28108.

  42. Bommareddy PK, Wakimoto H, Martuza RL, Kaufman HL, Rabkin SD, Saha D. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. J ImmunoTherapy Cancer. 2024;12:e008880.

  43. Mitra S, Leonard WJ. Biology of IL-2 and its therapeutic modulation: mechanisms and strategies. J Leukoc Biol. 2018;103(4):643–55.

    Article  PubMed  Google Scholar 

  44. Zou H, Mou XZ, Zhu B. Combining of oncolytic virotherapy and other immunotherapeutic approaches in cancer: a powerful functionalization tactic. Global Challenges. 2022;7:2200094.

  45. Andtbacka RHI, Amatruda T, Nemunaitis J, Zager JS, Walker J, Chesney JA, et al. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. EBioMedicine. 2019;47:89–97.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Related Posts